logo
Baby born with rare disorder thrives after getting personalized gene editing treatment

Baby born with rare disorder thrives after getting personalized gene editing treatment

Yahoo16-05-2025

The Brief
KJ Muldoon was diagnosed with a rare genetic disorder when he was born called severe CPS1 deficiency.
KJ is one in a million babies that are diagnosed with this illness.
Researchers and doctors used CRISPR gene editing to create a customized treatment for KJ.
A baby born with a rare and dangerous genetic disease is thriving after receiving an experimental gene editing treatment that was made just for him.
In a study published in the New England Journal of Medicine on Thursday, researchers said the baby's case is among the first to be successfully treated with a custom therapy that seeks to fix a tiny but critical error in his genetic code.
KJ Muldoon of Clifton Heights, Pennsylvania, was diagnosed with severe CPS1 deficiency shortly after being born. Within six months, a team at Children's Hospital of Philadelphia (CHOP) and Penn Medicine, as well as their partners, created a therapy specifically designed to correct KJ's faulty gene through CRISPR.
Dig deeper
People diagnosed with severe CPS1 deficiency lack an enzyme that is needed to help remove ammonia from their bodies.
This deficiency then leads to a build up of ammonia in their blood and becomes toxic. A liver transplant is another option to treat this illness.
By the numbers
About one in a million babies are diagnosed with this rare disease.
CRISPR is a gene editing tool that won its inventors the Nobel Prize in 2020.
Instead of cutting the DNA strand like the first CRISPR approaches, doctors employed a technique that flips the mutated DNA "letter" — also known as a base — to the correct type.
Known as "base editing," it reduces the risk of unintended genetic changes.
The backstory
Gene therapies, which can be extremely expensive to develop, generally target more common disorders in part for simple financial reasons: more patients mean potentially more sales, which can help pay the development costs and generate more profit.
The first CRISPR therapy approved by the U.S. Food and Drug Administration, for example, treats sickle cell disease, a painful blood disorder affecting millions worldwide.
Dr. Kiran Musunuru, a University of Pennsylvania gene editing expert who co-authored the study about KJ's treatment, said his team's work — funded in part by the National Institutes of Health — showed that creating a custom treatment doesn't have to be prohibitively expensive.
The cost was "not far off" from the $800,000-plus for an average liver transplant and related care, he said.
"As we get better and better at making these therapies and shorten the time frame even more, economies of scale will kick in and I would expect the costs to come down," Musunuru said.
Timeline
In February, KJ got his first IV infusion with the gene editing therapy, delivered through tiny fatty droplets called lipid nanoparticles that are taken up by liver cells.
After follow-up doses in March and April, KJ has been able to eat more normally and has recovered well from illnesses like colds, which can strain the body and exacerbate symptoms of CPS1. The 9 ½-month-old also takes less medication.
Considering his poor prognosis earlier, "any time we see even the smallest milestone that he's meeting – like a little wave or rolling over – that's a big moment for us," his mother said.
What's next
Despite the positive results, researchers caution that it's only been a few months since KJ began receiving this new treatment. He'll need to be under observation for years.
What they're saying
"We're still very much in the early stages of understanding what this medication may have done for KJ," Dr. Rebecca Ahrens-Nicklas, a gene therapy expert at CHOP, said. "But every day, he's showing us signs that he's growing and thriving."
The Source
Information for this article was taken from a Children's Hospital of Philadelphia news release and The Associated Press. This story was reported from Los Angeles.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Tiny fragment of asteroid giving Field Museum scientists a glimpse 4.6 billion years into the past
Tiny fragment of asteroid giving Field Museum scientists a glimpse 4.6 billion years into the past

CBS News

time20 minutes ago

  • CBS News

Tiny fragment of asteroid giving Field Museum scientists a glimpse 4.6 billion years into the past

The Field Museum is the new temporary home to a tiny piece of pristine asteroid. The fragment of the asteroid Bennu, on loan from NASA, won't be on display for visitors, but will give scientists the chance to study an asteroid sample uncontaminated by Earth's atmosphere. A tiny, black fragment might not seem exciting, until a scientist explains it's a specimen from space. "It's an honor of a lifetime to be able to study this sample," said Field Museum curator Dr. Philipp Heck. How did Heck feel when the little rock first arrived at the museum and he held the vial containing the sample? "It was amazing. I was looking forward to that moment for a long time," he said. NASA's OSIRIS-REx mission was planned decades ago. In 2016, a spacecraft launched. In 2018, it arrived at Bennu, a near-Earth asteroid as wide as the Sears Tower is tall. The mission collected pieces of the asteroid and brought them back to Earth in 2023. "This is the first U.S. mission that sends a spacecraft to the asteroid and brings a sample back to Earth," said University of Chicago graduate student Yuke Zheng, who is part of the OSIRIS-REx sample analysis team. "It's a tiny, dark, black fragment that is fragile, so we want to protect it very carefully." She'll use the museum's scanning electron microscope to get an up-close look at a tiny sample of Bennu. "What struck me is how dark the sample is. I had never seen such a dark sample," Heck said. The fragment is like a time capsule, taking scientists back 4.6 billion years. "We believe Bennu contains part of the ingredients for life, and part of the ingredients of the formation of Earth," Heck said. Suddenly, a fragment at the bottom of a vial can have you pondering your place in the universe. "I've never studied a pristine sample from an asteroid," Heck said.

Cook County jury awards $20.5 million to family of girl who died from toxic levels of morphine
Cook County jury awards $20.5 million to family of girl who died from toxic levels of morphine

CBS News

time22 minutes ago

  • CBS News

Cook County jury awards $20.5 million to family of girl who died from toxic levels of morphine

A Cook County jury awarded more than $20 million in damages to the family of an 11-year-old girl who died from toxic levels of morphine. In October 2020, Ava Wilson was recovering from leukemia when she went for a follow-up appointment at Advocate Children's Hospital. During her appointment, she was crying from pain, and had difficulty walking, according to her family's attorneys. Lab tests revealed she had low platelet counts, low blood cell counts, high liver enzymes, and low blood pressure. She was discharged from Advocate Children's Hospital with instructions to take 15 milligrams of morphine every four hours, triple the amount of her previous prescriptions. A nurse practitioner also increased her gabapentin prescription. Approximately 36 hours after getting home, she died in her sleep from acute drug toxicity of several substances, including lethal levels of morphine in her system at the time of her death. Her family's attorneys said the hospital should have admitted Ava to the hospital to get her blood pressure under control and treat the cause of her pain, but simply sent her home with excessive pain medications. "Ava's body was yelling out to these clinicians, 'help me!', and they just ignored it," attorney Matthew Williams said. After a civil trial, a jury awarded her family $20.5 million in damages. "While nothing will ease the depth of Ava's loved ones' pain, the family appreciates that the jury recognized that Ava's death was preventable and that she should still be with them today," attorney Aaron Boeder said.

Fast Five Quiz: Late-Onset Pompe Disease
Fast Five Quiz: Late-Onset Pompe Disease

Medscape

time23 minutes ago

  • Medscape

Fast Five Quiz: Late-Onset Pompe Disease

Multiple genetic variants have been associated with LOPD. However, the c.-32-13T>G splice site variant is found in up to 90% of adults and 50% of pediatric patients. Patients with LOPD often have compound heterozygous genotypes, with one allele carrying the common c.-32-13T>G splice-site variant and the other harboring a more deleterious GAA mutation (eg, nonsense, frameshift, or large deletion). Other variants— such as and c.1935C>A — are more commonly seen in infantile forms of Pompe disease. Learn more about the pathophysiology of LOPD. Diagnosis of LOPD typically follows a two-step approach: first, measuring GAA enzyme activity (often via dried blood spot assay) followed by confirmatory molecular genetic testing to identify pathogenic GAA variants. Although once considered a first-line diagnostic tool for LOPD, muscle biopsy is no longer preferred due to its invasive nature and the non-specificity of histologic findings. Muscle biopsy may still be considered in rare, ambiguous cases when enzyme and genetic testing are inconclusive or conflicting. CK levels might be elevated in some patients but are nonspecific and primarily serve to raise clinical suspicion. Learn more about the workup for LOPD. Enzyme replacement therapy (ERT) has significantly changed the natural history of the disease by improving survival and stabilizing motor and respiratory function. However, key limitations in skeletal muscle uptake and variability in clinical response remain. This is due to low expression of the mannose-6-phosphate receptor in muscle tissue, which hampers enzyme internalization. As a result, patients might experience a limited or plateaued response. Newer approaches, including modified ERT and gene therapy, are being developed to address this issue. High toxicity to cardiac muscle, uniform patient response, and development of cardiac hypertrophy have not been reported as key limitations. Learn more about treatment options for LOPD. NBS programs have reshaped the understanding of Pompe disease, particularly LOPD. A significant proportion of screen-positive newborns harbor genetic variants associated with LOPD, including pseudo deficiency alleles and variants of uncertain significance. These individuals are often asymptomatic at birth and might not develop symptoms for years, if at all. This has raised important clinical questions around monitoring, counseling, and when (or whether) to initiate therapy; expanded screening has also revealed that the true prevalence of LOPD might be higher than historical estimates suggested. Learn more about the management of LOPD. Editor's Note: This article was created using several editorial tools, including generative AI models, as part of the process. Human review and editing of this content were performed prior to publication. Lead image: UCSF/Science Source

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store